Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Corcept Therapeutics, retaining the price target of $137.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Edward Nash has given his Buy rating due to a combination of factors related to Corcept Therapeutics’ promising developments and strategic plans. The company has made significant progress with its novel glucocorticoid modulator, relacorilant, which has seen advancements in both clinical and regulatory arenas. Notably, the FDA has accepted an NDA submission for relacorilant in treating Cushing’s syndrome, with a decision expected by the end of 2025.
Additionally, Corcept has submitted another NDA for relacorilant in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer. The company is gearing up for a potential launch in mid-2026, supported by a newly established oncology leadership team and a planned sales force to target oncologists. The potential for relacorilant’s expansion in oncology, including ongoing studies and combination strategies, further supports the positive outlook and Buy rating.
According to TipRanks, Nash is a 5-star analyst with an average return of 14.9% and a 45.35% success rate. Nash covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Cardiol Therapeutics, and Madrigal Pharmaceuticals.
In another report released on August 5, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $82.00 price target.